natgillin/translations-raw huggingface dataset:
• Your heart rate is abnormally low (usually lower than 60 beats per minute) and you do not already have in place a device that paces your heart (pacemaker). 
• e imate nenormalno poasen srni utrip (po navadi manj kot 60 utripov na minuto) in še nimate nameš ene naprave, ki spodbuja srce (spodbujevalnika).
A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Possia therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba bodisi za prenehanje dojenja bodisi za prekinitev/prenehanje zdravljenja z zdravilom Possia, upoštevaje koristi dojenja za otroka in koristi zdravljenja za žensko.
• The starting dose is two tablets at the same time (loading dose of 180 mg). 
• Začetni odmerek sta dve tableti hkrati (polnilni odmerek 180 mg).
Patients taking Possia should also take ASA daily, unless specifically contraindicated. 
Bolniki, ki jemljejo zdravilo Possia, morajo jemati tudi ASA, če ni posebej kontraindicirana.
This will tell you whether you have taken the 
Tako boste videli, ali ste odmerek že vzeli.
Do not throw away any medicinesvia wastewater or household waste. 
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
For further information, please refer to section 5.1. 
Za dodatne informacije glejte poglavje 5.1.
The safety and efficacy of Possia in children below the age of 18 in the approved adult indication has not been established. 
Varnost in učinkovitost zdravila Possia pri otrocih do 18. leta starosti nista ugotovljeni za indikacije, odobrene za odrasle.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines that increase your risk of bleeding: 
Še zlasti morate svojemu zdravniku ali farmacevtu povedati, če uporabljate katero od naslednjih zdravil, ki povečajo tveganje krvavitev:
These increases are not considered clinically significant. 
Ta povečanja ne veljajo za klinično pomembna.
Investigations 
Preiskave
This includes medicines that you buy without a prescription, dietary supplements and herbal remedies. 
To velja tudi za zdravila, ki ste jih dobili brez recepta, za prehranske dodatke in za zeliščna zdravila.
Frequency categories are defined according to the following conventions: Very common (≥1/10), Common (≥1/100 to 1/10), Uncommon (≥1/1,000 to 1/100), Rare (≥1/10,000 to 1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from the available data). 
Kategorije pogostnosti so opredeljene po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000), ni znano (ni mogoče oceniti na podlagi podatkov, ki so na voljo).
Take Possia on a regular basis and for as long as your doctor keeps prescribing it. 
Zdravilo Possia jemljite redno in toliko časa, kot vam ga zdravnik predpisuje.
Overall outcome of bleeding rates in the PLATO study are shown in Table 2. 
Krvavitve Celotne rezultate deležev krvavitev v študiji PLATO prikazuje preglednica 2.
These differences are not considered clinically significant (see section 4.2). 
Te razlike ne veljajo za klinično pomembne (glejte poglavje 4.2).
Similar increases in AUC and Cmax were observed for all atorvastatin acid metabolites. 
Podobna povečanja AUC in Cmax so ugotovili za vse presnovke atorvastatina.
Do not stop taking Possia without talking to your doctor. 
Ne prenehajte jemati zdravila, ne da bi se posvetovali s svojim zdravnikom.
Date of first authorisation: 3 December 2010 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 03 december 2010
These very small blood cells help stop bleeding by clumping together to plug tiny holes in blood vessels that are cut or damaged. 
Te zelo majhne krvne celice pomagajo ustaviti krvavitev tako, da se sprimejo in zamašijo drobne odprtine v prerezanih ali poškodovanih žilah.
Recoveries of ticagrelor and the active metabolite in urine were both less than 1% of the dose. 
Pojavljanje tikagrelorja in aktivnega presnovka v urinu je bilo za oba manj kot 1 % odmerka.
• Feeling short of breath - this is common. 
• Kratko sapo - to je pogosto.
The mechanism for uterine tumors is likely hormonal imbalance which can lead to tumors in rats. 
Mehanizem nastanka tumorjev maternice je verjetno hormonsko neravnovesje, ki lahko pri podganah povzroči tumorje.
Ticagrelor produced irregular cycles (mostly extended cycles) in female rats, but did not affect overall fertility in male and female rats. 
Tikagrelor je pri podganjih samicah povzročil neredne cikluse (večinoma podaljšane), ni pa vplival na celotno plodnost podganjih samcev ali samic.
Possia may have similar effect on lovastatin. 
Zdravilo Possia morda podobno vpliva na lovastatin.
This suggests it is appropriate to treat patients with ticagrelor for up to 12 months (see section 4.2). 
To kaže, da je bolnike ustrezno s tikagrelorjem zdraviti do 12 mesecev (glejte poglavje 4.2).
• Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached 
• v 60 dneh po doseženem pomembnem mejniku (farmakovigilančnem ali povezanem z zmanjševanjem tveganja),
Multiple related adverse reaction terms have been grouped together in the table and include medical terms as described below: 
Več sorodnih izrazov za neželene učinke je v preglednici skupaj razvrščenih v skupine in vključujejo spodaj navedene medicinske izraze:
The primary route of elimination for the active metabolite is most likely via biliary secretion. 
Primarna pot odstranjevanja aktivnega presnovka je najverjetneje z biliarno sekrecijo.
Ticagrelor is also a P-gp substrate and a weak P-gp inhibitor and may increase the exposure of P-gp substrates. 
Tikagrelor je tudi substrat P-gp in šibek zaviralec P-gp in lahko poveča izpostavljenost substratom P-gp.
Therefore, premature discontinuation of treatment 
Zato se je treba izogniti prezgodnjemu prenehanju zdravljenja.
If clinically indicated, Possia should be used with caution in the following patient groups: 
Če je zdravilo Possia klinično indicirano, ga je treba previdno uporabljati v naslednjih skupinah bolnikov:
Also tell your doctor that because you are taking Possia, you may have an increased risk of bleeding if your doctor gives you fibrinolytics, often called ‘clot dissolvers', such as streptokinase or alteplase. 
Zdravniku tudi povejte, da imate lahko zaradi jemanja zdravila Possia večje tveganje krvavitev, če vam zdravnik da fibrinolitike (pogosto jih imenujejo tudi "zdravila za raztapljanje strdkov"), kakršna sta streptokinaza ali alteplaza.
The European Medicines Agency has waived the obligation to submit the results of studies with Possia in all subsets of the paediatric population in the granted indication (see section 4.2 and 5.2). 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom Possia za vse skupine pediatrične populacije pri odobreni indikaciji (glejte poglavji 4.2 in 5.2).
All-cause mortality d 
Umrljivost zaradi vseh vzrokov
The mean t1/2 was approximately 7 hours for ticagrelor and 8.5 hours for the active metabolite. 
Povprečni t1/2 je bil približno 7 ur za tikagrelor in 8,5 ure za aktivni presnovek.
This is a substance present in many medicines used to prevent blood clotting. 
To je učinkovina, ki jo vsebujejo številna zdravila za preprečevanje krvnih strdkov.
It is usually mild to moderate in intensity and often resolves without need for treatment discontinuation. 
Po navadi je blaga do zmerna in pogosto mine, ne da bi bilo treba zdravljenje prekiniti.
The result appeared early (absolute risk reduction [ARR] 0.6% and Relative Risk Reduction [RRR] of 12% at 30 days), with a constant treatment effect over the entire 12 month period, yielding ARR 1.9% per year with RRR of 16%. 
Rezultat se je pojavil zgodaj (absolutno zmanjšanje tveganja [ARR - Absolute Risk Reduction] 0,6 % in relativno zmanjšanje tveganja [RRR - Relative Risk Reduction] 12 % po 30 dneh), s stalnim terapevtskim učinkom med celotnim 12-mesečnim obdobjem, kar pomeni ARR 1,9 % na leto in RRR 16 %.
It might be due to your heart disease or another cause, or it might be a side effect of Possia. 
Lahko je posledica bolezni srca ali kakšnega drugega vzroka, lahko pa je tudi neželen učinek zdravila Possia.
When radiolabeled ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (57.8% in faeces, 26.5% in urine). 
Po uporabi radioaktivno označenega tikagrelorja je povprečni delež izločene radioaktivnosti 84 % (57,8 % v blatu, 26,5 % v urinu).
Combined efficacy and safety composite 
Kombinirano učinkovitost in varnost skupaj
No evidence of clinically significant adverse interactions with these medicinal products was observed. 
Znakov klinično pomembnega neželenega medsebojnega delovanja s temi zdravili niso opazili.
Fatal CABG bleeding occurred in 6 patients in each treatment group (see section 4.4). 
S CABG povezana krvavitev s smrtnim izidom se je pojavila pri 6 bolnikih v vsaki terapevtski skupini (glejte poglavje 4.4).
The mean absolute bioavailability of ticagrelor was estimated to be 36%. 
Ocenjena povprečna absolutna biološka uporabnost tikagrelorja je bila 36 %.
Lapses in therapy should also be avoided. 
Izogibati se je treba tudi izpuščanju odmerkov.
• You are allergic (hypersensitive) to ticagrelor or any of the other ingredients of Possia (listed in section 6). 
• e ste alergini (preobutljivi) na tikagrelor ali katerokoli sestavino zdravila Possia (naštete so v poglavju 6).
Round, biconvex, yellow tablets marked with ‘90' above ‘T' on one side and plain on the other. 
Okrogla, bikonveksna rumena tableta z oznako "90" nad "T" na eni strani in brez oznak na drugi strani.
This medicinal product does not require any special storage conditions. 
Za shranjevanje zdravila niso potrebna posebna navodila.
However, severe bleeding is uncommon, but can be life threatening. 
Hude krvavite pa so sicer le občasne, a so lahko smrtno nevarne.
Within these subgroups renal-related serious adverse events and adverse events leading to discontinuation of study drug were similar between treatment groups. 
V teh podskupinah so bili resni ledvični neželeni učinki in neželeni učinki, ki so povzročili prenehanje uporabe raziskovanega zdravila, med terapevtskima skupinama podobni.
Therefore, the use of Possia in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events. 
Zato je treba uporabo zdravila Possia pri bolnikih z večjim tveganjem krvavitev pretehtati v primerjavi s koristmi preprečevanja aterotrombotičnih dogodkov.
• ‘oral anticoagulants' often referred to as 'blood thinners' which include warfarin. 
• "peroralne antikoagulanse" (pogosto jih imenujejo "zdravila za redčenje krvi"), med katere spada varfarin.
• the clot can partly block the blood vessels to the heart - this reduces the blood flow to the heart and can cause chest pain which comes and goes (called ‘unstable angina'). 
• strdek delno zamaši srčno žilo - to zmanjša pretok krvi v srčno mišico in lahko povzroči bolečine v prsih, ki pridejo in minejo (to imenujemo "nestabilna angina pektoris").
Medicinal products metabolised by CYP2C9 
Zdravila, ki se presnavljajo s CYP2C9
A weakly significant treatment interaction was observed with region whereby the HR for the primary endpoint favours ticagrelor in the rest of world but favours clopidogrel in North America, which represented approximately 10% of the overall population studied (interaction p-value=0.045). 
Šibko značilno terapevtsko interakcijo so ugotovili z regijo, pri čemer je razmerje ogroženosti za primarni opazovani dogodek v korist tikagrelorja v preostalih delih sveta, v korist klopidogrela pa v Severni Ameriki, ki je predstavljala približno 10 % celotne raziskovane populacije (vrednost p za interakcijo = 0,045).
BLISTER (10 TABLETS) 
PRETISNI OMOT (10 TABLET)
Treating 54 ACS patients with ticagrelor instead of clopidogrel will prevent 1 atherothrombotic event; treating 91 will prevent 1 CV death (see Figure 1 and Table 3). 
Zdravljenje 54 bolnikov z akutnimi koronarnimi sindromi s tikagrelorjem namesto s klopidogrelom bo preprečilo 1 aterotrombotičen dogodek, zdravljenje 91 bolnikov bo preprečilo 1 kardiovaskularno smrt (glejte sliko 1 in preglednico 3).
Switching from clopidogrel to ticagrelor results in an absolute IPA increase of 26.4% and switching from ticagrelor to clopidogrel results in an absolute IPA decrease of 24.5%. 
Prehod s klopidogrela na tikagrelor povzroči absolutno povečanje IPA za 26,4 %, prehod s tikagrelorja na klopidogrel pa absolutno zmanjšanje IPA za 24,5 %.
Pharmacotherapeutic group: Platelet aggregation inhibitors excluding heparin, ATC code: B01AC24 
Farmakoterapevtska skupina: zaviralci agregacije trombocitov brez heparina Oznaka ATC: B01AC24
The steady state volume of distribution of ticagrelor is 87.5 l. Ticagrelor and the active metabolite is extensively bound to human plasma protein (>99.0%). 
Volumen porazdelitve tikagrelorja v stanju dinamičnega ravnovesja je 87,5 l. Tikagrelor in njegov aktivni presnovek sta v veliki meri vezana na človeške beljakovine v plazmi (> 99,0 %).
In 2.2% of patients, investigators considered the dyspnoea causally related to treatment with Possia. 
Pri 2,2 % bolnikov so raziskovalci dispnejo ocenili za vzročno povezano z uporabo zdravila Possia.
Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
If a patient is to undergo elective surgery and antiplatelet effect is not desired, Possia should be discontinued 7 days prior to surgery (see section 5.1). 
Če ima bolnik predvideno elektivno operacijo in antiagregacijski učinek ni zaželen, je treba uporabo zdravila Possia prekiniti 7 dni pred operacijo (glejte poglavje 5.1).
A patient who misses a dose of Possia should take only one 90 mg tablet (their next dose) at its scheduled time. 
Če bolnik izpusti odmerek zdravila Possia, naj vzame le eno 90-mg tableto (svoj naslednji odmerek) ob predvidenem času.
• You can check when you last took a tablet of Possia by looking on the blister. 
• Kdaj ste vzeli zadnjo tableto zdravila Possia, lahko preverite tako, da pogledate na pretisni omot.
The MAH must ensure that the system of pharmacovigilance presented in Module 1.8.1 of the Marketing Authorisation, is in place and functioning before and whilst the medicinal product is 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, ki je predložen v modulu 1.8.1 vloge za pridobitev dovoljenja za promet z zdravilom, vzpostavljen in deluje, preden da zdravilo v promet in ves čas trženja zdravila.
You may be at increased risk of bleeding. 
Obstaja lahko večje tveganje krvavitev.
• Patients with a propensity to bleed (e.g. due to recent trauma, recent surgery, coagulation disorders, active or recent gastrointestinal bleeding). 
• Bolniki, nagnjeni h krvavitvam (npr. zaradi nedavne poškodbe, nedavne operacije, koagulacijskih motenj, aktivne ali nedavne gastrointestinalne krvavitve).
Antifibrinolytic therapy (aminocaproic acid or tranexamic acid) and/or recombinant factor VIIa may increase haemostasis. 
Antifibrinolitično zdravljenje (aminokaprojska kislina ali traneksaminska kislina) in/ali rekombinantni faktor VIIa lahko povečajo hemostazo.
No information is available concerning treatment of patients on renal dialysis and therefore Possia is not recommended in these patients. 
Informacij o zdravljenju bolnikov na dializi ni, zato zdravila Possia pri teh bolnikih ni priporočljivo uporabljati.
These differences are not considered clinically significant. 
Te razlike ne veljajo za klinično pomembne.
Absorption of ticagrelor is rapid with a median tmax of approximately 1.5 hours. 
Absorpcija tikagrelorja je hitra in mediani tmax je približno 1,5 ure.
Age, sex, weight, race, geographic region, concurrent conditions, concomitant therapy, and medical history, including a previous stroke or transient ischaemic attack, all did not predict either overall or non-procedural PLATO Major bleeding. 
Starost, spol, telesna masa, rasa, geografska regija, sočasne bolezni, sočasna zdravljenja in zdravstvena anamneza, vključno s predhodno možgansko kapjo ali tranzitorno ishemično atako, niso bili napovedniki ne vseh in ne s postopki nepovezanih krvavitev po PLATO.
• After this starting dose, the usual dose is one tablet of 90 mg twice a day for up to 12 months unless your doctor tells you differently. 
• Po tem začetnem odmerku je običajen odmerek ena tableta 90 mg dvakrat na dan do 12 mesecev,
Similar to the overall PLATO study, total PLATO Major bleeding did not differ between ticagrelor and clopidogrel, regardless of CYP2C19 or ABCB1 genotype. 
Podobno kot v študij PLATO v celoti se vse hude krvavitve po PLATO med tikagrelorjem in klopidogrelom niso razlikovale, ne glede na genotip CYP2C19 ali ABCB1.
EU/1/10/656/005 168 film-coated tablets EU/1/10/656/006 100x1 film-coated tablets 
EU/1/10/656/001 60 filmsko obloženih tablet EU/1/10/656/002 180 filmsko obloženih tablet EU/1/10/656/003 14 filmsko obloženih tablet EU/1/10/656/004 56 filmsko obloženih tablet EU/1/10/656/005 168 filmsko obloženih tablet EU/1/10/656/006 100x1 filmsko obložena tableta
• unstable angina (angina or chest pain that is not well controlled). 
• nestabilno angino pektoris (tj. bolečino v prsih, ki ni dobro obvladana).
Following oral administration of ticagrelor 90 mg under fasted conditions, Cmax is 529 ng/ml and AUC is 3451 ng*h/ml. 
Po peroralni uporabi 90 mg tikagrelorja na tešče je Cmax 529 ng/ml in AUC 3451 ng.h/ml.
The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP agreed by the Committee for Medicinal Products for Human 
Imetnik dovoljenja za promet z zdravilom bo izvedel študije in dodatne farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, sprejetem v RMP, predloženem v modulu 1.8.2 vloge za pridobitev dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP v soglasju z Odborom za zdravila za uporabo v humani medicini (CHMP).
Holter Substudy 
Holterska podštudija
Treatment is recommended for up to 12 months unless discontinuation of Possia is clinically indicated (see section 5.1). 
Zdravljenje je priporočljivo nadaljevati do 12 mesecev, razen če je prenehanje uporabe zdravila Possia klinično indicirano (glejte poglavje 5.1).
- sudden numbness or weakness of your arm, leg or face, especially if only on one side of the 
• Znake možganske kapi, na primer: - nenadno omrtvelost ali šibkost roke, noge ali obraza, še zlasti, če se pojavi le na eni strani
Co-administration of Possia and levonorgestrel and ethinyl estradiol increased ethinyl estradiol exposure approximately 20% but did not alter the pharmacokinetics of levonorgestrel. 
Sočasna uporaba zdravila Possia ter levonorgestrela in etinilestradiola je povečala izpostavljenost etinilestradiolu za približno 20 %, farmakokinetike levonorgestrela pa ni spremenila.
If a CABG procedure is planned, ticagrelor bleeding risk is increased compared to clopidogrel when discontinued within less than 96 hours prior to procedure. 
Če je načrtovana koronarna obvodna operacija (CABG), je tveganje krvavitev s tikagrelorjem večje kot s klopidogrelom, če se uporaba preneha v manj kot 96 urah pred posegom.
The mechanism for the hepatic adenomas is likely due to a rodent-specific enzyme induction in the liver. 
Mehanizem nastanka jetrnih adenomov je verjetno posledica za glodalce specifične encimske indukcije v jetrih.
AstraZeneca AB Gärtunavägen SE-151 85 Södertälje Sweden or 
AstraZeneca AB Gärtunavägen SE-151 85 Södertälje Švedska ali
Switching from prasugrel to Possia has not been investigated. 
Prehod s prasugrela na zdravilo Possia ni raziskan.
This is because of the increased risk of bleeding. 
Obstaja namreč večje tveganje krvavitev.
There are no or limited amount of data from the use of ticagrelor in pregnant women. 
O uporabi tikagrelorja pri nosečnicah podatkov ni ali jih je malo.
Studies in animals have shown reproductive toxicity (see section 5.3). 
Študije na živalih so pokazale reproduktivne toksične učinke (glejte poglavje 5.3).
• You have had a stroke caused by bleeding in the brain. 
• če ste kdaj imeli možgansko kap zaradi krvavitve v možganih.
The Cmax of the active metabolite was unchanged and the AUC was decreased by 46%, respectively. 
Cmax aktivnega presnovka se ni spremenila, njegova AUC pa se je zmanjšala za 46 %.
Ticagrelor demonstrates linear pharmacokinetics and exposure to ticagrelor and the active metabolite (AR-C124910XX) are approximately dose proportional up to 1260 mg. 
Tikagrelor ima linearno farmakokinetiko in izpostavljenost tikagrelorju in njegovemu aktivnemu presnovku (AR-C124910XX) sta približno sorazmerni odmerku do 1260 mg.
• Patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and/or fibrinolytics) within 24 hours of Possia dosing. 
• Bolniki, sočasno zdravljeni z zdravili, ki lahko povečajo tveganje krvavitev (npr. nesteroidna protivnetna zdravila (NSAID), peroralni antikoagulansi in/ali fibrinolitiki) v 24 urah od uporabe zdravila Possia.
If you forget to take Possia 
Če ste pozabili vzeti zdravilo Possia
Ask your pharmacist how to throw away medicines you no longer use . 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
Total MI includes silent MI, with date of event set to date when discovered. 
Vsi MI vključujejo neme MI, pri čemer je kot datum dogodka upoštevan datum ugotovitve.
Similarly, when removing all procedure related bleeds, more bleeding occurred with ticagrelor than with clopidogrel (Table 2). 
Tudi po izločitvi vseh s postopki povezanih krvavitev je bilo, podobno, več krvavitev s tikagrelorjem kot s klopidogrelom (preglednica 2).
Exploratory analyses suggest a possible association with ASA dose such that reduced efficacy was observed with ticagrelor with increasing ASA doses. 
Eksploratorne analize so pokazale možno povezavo med odmerkom ASA, tako da je bila opažena manjša učinkovitost tikagrelorja z večanjem odmerkov ASA.
Reproductive system and breast disorders Vaginal bleeding (including metrorrhagia) 
Motnje reprodukcije in dojk nožnična krvavitev (vključno z metroragijo)
Possia is expected to have no or negligible influence on the ability to drive and use machines. 
Za zdravilo Possia se pričakuje, da nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
CYP3A4 is the major enzyme responsible for ticagrelor metabolism and the formation of the active metabolite and their interactions with other CYP3A substrates ranges from activation through to inhibition. 
CYP3A4 je glavni encim, odgovoren za presnovo tikagrelorja in nastanek aktivnega presnovka; njuna medsebojna delovanja z drugimi substrati CYP3A segajo od aktivacije do zavrtja.
Figure 1 - Time to first occurrence of CV death, MI and Stroke (PLATO) 
Čas do prvega pojava kardiovaskularne smrti, MI in možganske kapi (PLATO)
- sudden confusion, difficulty speaking or understanding others - sudden difficulty in walking or loss of balance or co-ordination - suddenly feeling dizzy or sudden severe headache with no known cause These are signs of a kind of stroke caused by bleeding into the brain. 
- nenadno zmedenost, težave z govorjenjem ali razumevanjem tistega, kar vam povedo drugi, - nenadne težave s hojo ali izgubo ravnotežja ali koordinacije gibov, - nenadno omotico ali nenaden hud glavobol brez znanega vzroka.
Few patients in PLATO had fatal bleeds: 20 (0.2%) for ticagrelor and 23 (0.3%) for clopidogrel (see section 4.4). 
Malo bolnikov v PLATO je imelo krvavitve s smrtnim izidom: 20 (0,2 %) pri tikagrelorju in 23 (0,3 %) pri klopidogrelu (glejte poglavje 4.4).
Chronic daily ASA doses to accompany Possia should be 75-150 mg (see section 4.2 and 4.4). 
Kronični dnevni odmerki ASA ob uporabi zdravila Possia morajo biti od 75 do 150 mg (glejte poglavji 4.2 in 4.4).